Skip to main content

Table 1 Baseline characteristics of the study population: patients with at least 6 months OS (N = 361)

From: Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial

  CoC-Group (N = 251) non-CoC-Group (N = 110)
Median age, years (range; interquartile range) 63 (30–83; 56.1–68.7) 65 (40–86; 56.4–71.5)
Sex
 Male 164 (65%) 77 (70%)
 Female 87 (35%) 33 (30%)
WHO status
 0 139 (55%) 63 (57%)
 1 90 (36%) 40 (36%)
 2 2 (1%) 2 (2%)
 Missing data 20 (8%) 5 (5%)
Therapy arm   
 Capecitabine 127 (51%) 53 (48%)
 5-FU 124 (49%) 57 (52%)
Cohort
 Adjuvant 182 (73%) 36 (33%)
 Neoadjuvant 69 (27%) 74 (67%)
Tumour categorya
 T1 or T2 48 (19%) 12 (11%)
 T3 184 (73%) 89 (81%)
 T4 18 (7%) 8 (7%)
 Missing data 1 (< 1%) 1 (1%)
Nodal categorya
 Node negative 93 (37%) 45 (41%)
 Node positive 157 (63%) 60 (54%)
 Missing data 1 (< 1%) 5 (5%)
  1. Data are n (%) or median (range). aclinical or pathological category. WHO World Health Organization, FU fluorouracil. T - size or direct extent of the primary tumor